Literature DB >> 21562784

Fatty liver is associated with recurrent bacterial infections independent of metabolic syndrome.

William Nseir1, Hussein Taha, Julnar Khateeb, Maria Grosovski, Nimer Assy.   

Abstract

BACKGROUND: Diabetes mellitus and obesity are important components of metabolic syndrome (MetS) which are associated with infections. MetS is frequent in nonalcoholic fatty liver disease (NAFLD). AIMS: The objective of this study was to examine whether patients with NAFLD are at higher risk of recurrent bacterial infections (RBIs).
METHODS: Two-hundred and forty-seven from 296 hospitalized NAFLD patients were assessed over a three-year period for the occurrence of RBIs and were compared with 100 age and gender-matched patients without NAFLD, who were hospitalized over the same period because of a bacterial infection. An RBI was defined as: ≥2 episodes of bacterial infections per year for a period of three consecutive years. NAFLD was diagnosed by ultrasonography. Biomarkers of inflammation, the level of oxidative stress, insulin resistance, and serum vitamin D levels were measured.
RESULTS: NAFLD patients had significantly more RBIs than the patients without NAFLD (22% vs. 8%; P < 0.001). Univariate analysis showed that age, BMI, male waist circumference, serum 25(OH)D, triglycerides, serum malondialdehyde, and paraoxonase-1 are associated with RBIs in NAFLD patients. Multivariate analysis showed that NAFLD (odds ratio (OR) = 3.0, 95% confidence interval (CI) = 2.6-4.2, P < 0.001), serum 25(OH)D level <20 ng/mL (OR = 2.6; 95% CI 2.4-3.1, P = 0.01), obesity (BMI >30 kg/m(2) (OR = 2.2, 95% CI 1.8-2.9, P = 0.02) were associated with RBIs, irrespective of MetS.
CONCLUSIONS: NAFLD is associated with increased risk of RBIs irrespective of MetS. Vitamin D insufficiency is frequent in NAFLD and is associated with increased risk of RBIs.

Entities:  

Mesh:

Year:  2011        PMID: 21562784     DOI: 10.1007/s10620-011-1736-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  47 in total

1.  Criteria for definition of overweight in transition: background and recommendations for the United States.

Authors:  R J Kuczmarski; K M Flegal
Journal:  Am J Clin Nutr       Date:  2000-11       Impact factor: 7.045

Review 2.  NKT cells: what's in a name?

Authors:  Dale I Godfrey; H Robson MacDonald; Mitchell Kronenberg; Mark J Smyth; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

Review 3.  Obesity and infection.

Authors:  Matthew E Falagas; Maria Kompoti
Journal:  Lancet Infect Dis       Date:  2006-07       Impact factor: 25.071

Review 4.  Vitamin D deficiency.

Authors:  Michael F Holick
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

Review 5.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

6.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.

Authors:  I R Willner; B Waters; S R Patil; A Reuben; J Morelli; C A Riely
Journal:  Am J Gastroenterol       Date:  2001-10       Impact factor: 10.864

7.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

8.  An association of serum vitamin D concentrations < 40 nmol/L with acute respiratory tract infection in young Finnish men.

Authors:  Ilkka Laaksi; Juha-Petri Ruohola; Pentti Tuohimaa; Anssi Auvinen; Riina Haataja; Harri Pihlajamäki; Timo Ylikomi
Journal:  Am J Clin Nutr       Date:  2007-09       Impact factor: 7.045

9.  Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis.

Authors:  Michael Kremer; Emmanuel Thomas; Richard J Milton; Ashley W Perry; Nico van Rooijen; Michael D Wheeler; Steven Zacks; Michael Fried; Richard A Rippe; Ian N Hines
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

Review 10.  Leptin in the regulation of immunity, inflammation, and hematopoiesis.

Authors:  G Fantuzzi; R Faggioni
Journal:  J Leukoc Biol       Date:  2000-10       Impact factor: 4.962

View more
  11 in total

1.  Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis.

Authors:  Xiang Wang; Weiping Li; Ying Zhang; Yang Yang; Guijun Qin
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 2.  Infections at the nexus of metabolic-associated fatty liver disease.

Authors:  Robim M Rodrigues; Tamara Vanhaecke; Joost Boeckmans; Matthias Rombaut; Thomas Demuyser; Baptist Declerck; Denis Piérard; Vera Rogiers; Joery De Kock; Luc Waumans; Koen Magerman; Reinoud Cartuyvels; Jean-Luc Rummens
Journal:  Arch Toxicol       Date:  2021-05-24       Impact factor: 5.153

3.  Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: A cohort study.

Authors:  Yen-Chieh Lee; Jiun-Ling Wang; Yaa-Hui Dong; Hsi-Chieh Chen; Li-Chiu Wu; Chia-Hsuin Chang
Journal:  PLoS Med       Date:  2019-09-13       Impact factor: 11.069

Review 4.  NAFLD and Infection, a Nuanced Relationship.

Authors:  Abimbola Adenote; Igor Dumic; Cristian Madrid; Christopher Barusya; Charles W Nordstrom; Libardo Rueda Prada
Journal:  Can J Gastroenterol Hepatol       Date:  2021-04-15

5.  Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study.

Authors:  Juan Bañares; Ramiro Manzano-Nuñez; Alba Prió; Jesús Rivera-Esteban; Laura Camps-Relats; Ana Villarejo; Lourdes Ruiz-Ortega; Mònica Pons; Andreea Ciudin; María Teresa Salcedo; Víctor Vargas; Joan Genescà; Juan M Pericàs
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-24       Impact factor: 6.055

6.  Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome.

Authors:  Suchanart Jitrukthai; Chayanis Kositamongkol; Punyisa Boonchai; Euarat Mepramoon; Pinyapat Ariyakunaphan; Pongpol Nimitpunya; Weerachai Srivanichakorn; Thanet Chaisathaphol; Chaiwat Washirasaksiri; Chonticha Auesomwang; Tullaya Sitasuwan; Rungsima Tinmanee; Naruemit Sayabovorn; Phunchai Charatcharoenwitthaya; Pochamana Phisalprapa
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964

Review 7.  Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic.

Authors:  Musaab Ahmed; Mohamed H Ahmed
Journal:  World J Clin Cases       Date:  2021-06-16       Impact factor: 1.337

Review 8.  COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics.

Authors:  Piero Portincasa; Marcin Krawczyk; Wiktor Smyk; Frank Lammert; Agostino Di Ciaula
Journal:  Eur J Clin Invest       Date:  2020-08-26       Impact factor: 5.722

9.  Liver dysfunction and SARS-CoV-2 infection.

Authors:  Abraham Edgar Gracia-Ramos; Joel Omar Jaquez-Quintana; Raúl Contreras-Omaña; Moises Auron
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

10.  Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent Clostridioides difficile Infection.

Authors:  Lara Šamadan; Mia Jeličić; Adriana Vince; Neven Papić
Journal:  Antibiotics (Basel)       Date:  2021-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.